Vincent Trebosc

📢 🚀 We are hiring! 🔎 🙏 Scientific Officer (80-100%) 👉A rare opportunity to play a central part in coordinating the research activities of NCCR AntiResist. Come and join us! 👉nccr-antiresist.ch/join-us/ #TransformingAntimicrobialResearch #hiring #job #science #research

#JobAlert Research Scientist PK/PD in our R&D team at @Bioversys Lille (France) #AMR linkedin.com/posts/bioversy…

Well done @mulecc - your PhD work just published 😀nature.com/articles/s4146… I think we've only scratched the surface with this... H-NS allowing bacteria to direct their own evolution. Exciting times ahead...

We are seeking excellent candidates for three PostDoc positions at the Department of Drug Design and Optimization, HIPS. If you have a strong background in MedChem and synthesis of bioactive small molecules, then feel free to apply! helmholtz-hzi.de/en/career/jobs…

Bacteria often adapt to stress through 2-component regulatory systems (TCS). In Klebsiella pneumoniae, the EnvZ/OmpR TCS facilitates lung infection by transcriptionally regulating key virulence factors. Read the article in @JournalSpectrum: asm.social/1Ei

Out now! In vitro models that mimic within patient conditions should be used to revitalize antibiotic discovery and development nature.com/articles/s4156…

Announcing the conference: "New Approaches to Combat Antibiotic-Resistant Bacteria" for world-leading, novel AMR science. 🦠👩‍🔬🧑‍🔬 🗓️ 9-13 June 2024 🏡 Ascona, Switzerland Now open for abstract submissions! #AMR #TransformingAntimicrobialResearch biozentrum.unibas.ch/events/confere…

The Many Shapes of Bacteria #infographic #bacteria #microbes #biology #science #design #illustration #art #sciart #shapes #geometry #microbiology

If you are like me and do everything at the last minute, now is the time to apply to #AMR ICARe course (Oct 7-15). Full program is available at icarecourse.org and deadline for student application is June 21! @sylvainbrisse and I will teach genomic epi + hands on bioinf

👇Check it out: a call for a Junior Group Leader on Infectious diseases and/or antimicrobial resistance Institut Pasteur de Lille, France

Rappel pour nos amis chercheurs et étudiants : il est INTERDIT d'utiliser ce site qui permet d'accéder à tous les articles de recherche gratuitement ! Ce site est souvent bloqué par les fournisseurs internet, il est aussi interdit de contourner le blocage avec cette méthode. 🧵

"In just about every other therapeutic area, investors and drugmakers can rely on the market to reward the development of impactful medicines through strong sales," writes @deepalimpatel. "Not so with antimicrobials." #AMR efpia.eu/news-events/th… via @EFPIA

We're hiring! 📢 Would you like to work in a multicultural and dynamic team committed to addressing the growing threat of #antibioticresistance? If so, this is for you! 👇👇 gardp.org/work-with-us/

⏰Consultancy opportunity to work on the antibacterial pipeline review. Closing tomorrow! Please share in your network! @HatimSati @WHO

TRR261 announces and recommends the ICARe 2023 course!

And big thanks to @AnnaCVetter for the cool accumulation work!

Happy to share this new piece in the characterization of FhuE mediated hyperactivity of rifabutin against A. baumannii. @NicolasWilland @univ_lille @Helmholtz_HZI @Bioversys #AMR authors.elsevier.com/c/1gn7VoqiQEXvw

“I personally find it unacceptable that we would have drugs in hand that help a significant number of patients from not passing away — and we have to drop this for financial reasons, rather than scientific ones.” The unfortunate reality of the abx market ft.com/content/2730bf…

#BioVersys is delighted to announce the 1st patient dosed in Phase 2a clinical trial with BVL-GSK098. The trial is being run in South Africa with our partners @taskapplied, and in collaboration with @GSK. This study receives valuable funding from @EDCTP. lnkd.in/e34Ty-65

We are thrilled to announce our investment into @BioVersys! The antibiotics they are developing target some of the highest-priority drug-resistant pathogens and could deliver significant benefits to patients suffering from life-threatening infections. amractionfund.com/blog-2022/amr-… #AMR